Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023
    Facebook Twitter Instagram
    Your Biotech
    • Bio Technology

      Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

      June 8, 2023

      Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

      June 7, 2023

      Biotechs face challenges as the industry’s annual bash returns to Boston

      June 5, 2023

      The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

      June 5, 2023

      China reaching for biotech breakthroughs in space

      June 2, 2023
    • Pharmaceutical

      Pharma company owner duped of ₹1.1 crore

      November 11, 2022

      Novavax cuts full-year revenue forecast again amid weak demand

      November 10, 2022

      Aurobindo units recall products in US market for manufacturing issues

      November 9, 2022

      AASLD 2022 | Ascentage Pharma Releases Phase I Results of IAP Antagonist APG-1387 in an Oral Report Showing Potential for Functionally Curing CHB

      November 8, 2022

      Trade Spotlight | What should you do with Amara Raja, Sun Pharma Advanced Research, Poly Medicure on Monday?

      November 7, 2022
    Your Biotech
    Home»Bio Technology»Pfizer raises 2022 earnings guidance, beats third-quarter expectations
    Bio Technology

    Pfizer raises 2022 earnings guidance, beats third-quarter expectations

    yourbiotechBy yourbiotechNovember 2, 2022No Comments2 Mins Read
    Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp VKontakte Email
    Share
    Facebook Twitter LinkedIn Pinterest Email

    It now expects earnings per share of $6.40 to $6.50 for the year, up from its previous forecast of $6.30 to $6.45. The pharmaceutical company also raised the lower end of its sales guidance and now expects revenue of $99.5 billion to $102 billion for the year.

    Pfizer raised its full-year sales guidance for its Covid-19 vaccine to $34 billion this year, up $2 billion from the company’s previous expectations. It is maintaining revenue expectations of $22 billion for the antiviral pill Paxlovid.

    Its shares rose by about 2% in morning trading.

    Here’s how the company performed compared with what Wall Street expected for the third quarter, based on analysts’ average estimates compiled by Refinitiv:

    Adjusted EPS: $1.78 per share vs. $1.39 expected
    Revenues: $22.6 billion vs. $21 billion expected
    But Pfizer’s third-quarter global revenue fell 6% to $22.6 billion compared to the same period last year due to softening demand for its Covid vaccines internationally. The company sold $4.4 billion of its vaccine worldwide in the quarter, a decrease of 66% compared with the third quarter of 2021.

    But softer global Covid vaccine sales internationally were offset by strong demand in the U.S., where revenue increased 83% year over year due to the rollout of the new BA.5 omicron boosters. Paxlovid also had a strong quarter, generating $7.5 billion in sales worldwide though mostly in the U.S.

    Sales of the Eliquis, a blood thinner to treat clots and prevent strokes, came in at about $1.5 billion, a 9% increase over the same quarter last year. And Pfizer’s pneumonia vaccine, Prevnar, booked $1.6 billion in global sales, an increase of 11% over the same period in 2021.

    Pfizer had net income of $8.6 billion for the third quarter, a 6% increase over the same quarter last year.

    Pfizer CEO Albert Bourla indicated that company is looking beyond the Covid pandemic which has led to record windfalls for the pharmaceutical giant.

    Share. Facebook Twitter Pinterest LinkedIn Tumblr WhatsApp Email
    Previous ArticleBuy Sun Pharmaceutical Industries, target price Rs 1180: JM Financial
    Next Article Pfizer CEO reveals 2030 growth plan as company faces up to $18 billion revenue hit from generics
    yourbiotech
    • Website

    Related Posts

    Biotech’s trade secrets face growing threat from foreign influences, science leaders warn

    June 8, 2023

    Canadian biotech narrows trial population to lift solid tumor drug out of FDA hold

    June 7, 2023

    Biotechs face challenges as the industry’s annual bash returns to Boston

    June 5, 2023

    The Biotech Buying Bonanza: Why The FTC’s Amgen Battle Won’t Chill The Spree

    June 5, 2023

    Leave A Reply Cancel Reply

    Our Picks

    Subscribe to Updates

    Get the latest creative news from SmartMag about art & design.

    About Us
    About Us

    We provide a wide range of customized, integrated B2B and B2C digital marketing services solutions that are ideal for your business.

    We're accepting new partnerships right now.

    Email Us: info@yourmartech.com
    Contact: +1-530-518-1420

    Our Brands
    • Your Martech
    • Your HR Tech
    • Your Fin Tech
    • Your Revenue
    • Your Info Tech
    • Your POS Tech
    • Your Health Tech
    SUBSCRIBE NOW
    Loading
    LinkedIn
    • Privacy Policy
    © 2022 Vigarbiz Inc. Designed by Vigarbiz Media

    Type above and press Enter to search. Press Esc to cancel.